



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## The effectiveness of biologics for patients with severe asthma: study protocol for an umbrella review of systematic reviews and meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-096874
Article Type:	Protocol
Date Submitted by the Author:	20-Nov-2024
Complete List of Authors:	<p>Xiao, Qionghua; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School</p> <p>Xue, Bingyu; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School</p> <p>Huang, Yuanming; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School</p> <p>Wang, Minghang; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease)</p>
Keywords:	Asthma < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™  
Manuscripts

1

2

3

41The effectiveness of biologics for patients with severe asthma: study

5

62protocol for an umbrella review of systematic reviews and

7

8

93meta-analyses

10

11

124Qionghua Xiao<sup>1,2</sup>, Bingyu Xue<sup>1,2</sup>, Yuanming Huang<sup>1,2</sup>, Minghang Wang<sup>1\*</sup>

13

145<sup>1</sup>National Regional Medical Center of TCM (Pulmonary Disease), the First Affiliated

15

16Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.

176

18

197<sup>2</sup>The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou,

20

21Henan, China.

228

23

24

259\*Correspondence:

26

2710Minghang Wang

28

29

3011E-mail: [wmh107hn@163.com](mailto:wmh107hn@163.com)

31

32

3312Word count: 1618.

34

3513ABSTRACT

36

37

3814Introduction: Many systematic reviews and meta-analyses (SRs/MAs) have evaluated the efficacy

39

4015of biologic therapies for severe asthma. However, the overall quality of these SRs/MAs are unclear,

41

42

4316which may influence the selection of biologics and lead to misleading clinical decision. This

44

45

4617umbrella review aims to objectively evaluate the overall quality of these SRs/MAs and reassess the

47

4818efficacy of biologic therapy for severe asthma. Thus, this study will provide reliable evidence for

49

50

5119clinical practice.

52

5320Methods and analysis: A systematic search will be performed in PubMed, EMBASE, Cochrane

54

55

5621Library, Web of Science, and Scopus databases. Literature screening and data extraction will be

57

58

5922conducted according to inclusion and exclusion criteria. Then, we will evaluate the reporting quality,

60

methodological quality and evidence quality of these SRs/MAs using Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement, A Measurement Tool to Assess Reviews (AMSTAR) 2, and Grading of Recommendation Assessment, Development and Evaluation (GRADE) system, respectively. In addition, the re-meta-analysis of outcomes will be performed applying R 4.3.3.

**Ethics and dissemination:** Since this umbrella review will use publicly available data, ethics approval is not required. We will disseminate the results of this study through a peer-reviewed journal.

**PROSPERO registration number:** CRD42024607393.

**Keywords:** biologics, severe asthma, umbrella review, protocol

## Article Summary

### Strengths and limitations of this study

(1) This study is the first umbrella review of systematic reviews and meta-analyses (SRs/MAs) evaluating the efficacy of biologic therapy for patients with severe asthma.

(2) This umbrella review will objectively evaluate the overall quality of eligible SRs/MAs.

(3) Only articles in English will be included in this study and important studies published in other languages may be omitted.

(4) Some subjective factors may have an effect on the evaluation of literature quality.

## 1 INTRODUCTION

Asthma is a prevalent chronic respiratory disease characterized by chronic airway inflammation and airway hyperresponsiveness. It often has recurrent wheezing, shortness of breath, chest tightness, cough and other symptoms.<sup>[1]</sup> Asthma is a serious global health problem, affecting about 300 million

1  
2  
3  
4 45 people worldwide and causing about 250,000 deaths annually.<sup>[2]</sup> What's worse, patients with severe  
5  
6 46 asthma have more severe symptoms, more frequent exacerbations, and more serious medication side  
7  
8  
9 47 effects, which can interfere with patient's daily life, sleep, and physical activity.<sup>[3]</sup> A Dutch study  
10  
11  
12 48 showed that about 3.7% of people with asthma have severe asthma.<sup>[4]</sup> In addition, severe asthma  
13  
14 49 leads to very high medical costs. In a Canadian study, severe asthma accounts for more than 60% of  
15  
16  
17 50 the cost of asthma.<sup>[5]</sup>  
18  
19  
20 51 Severe asthma means patients that remain uncontrolled despite adhering to maximal optimized  
21  
22 52 high-dose inhaled corticosteroids (ICS)/long-acting beta-agonists(LABA) treatment and management  
23  
24  
25 53 of associated factors, or that worsen when high-dose treatment is decreased.<sup>[6]</sup> For these patients,  
26  
27 54 add-on therapy, mainly emerging biologics, are needed to provide new hope for the treatment of  
28  
29  
30 55 severe asthma. Biologics can block the immuno-inflammatory cascade in the pathological course of  
31  
32  
33 56 severe asthma by precisely targeting inflammatory cytokines.<sup>[6]</sup> Biologics for severe asthma mainly  
34  
35 57 include anti-immunoglobulin E (anti-IgE) treatment (omalizumab), anti-interleukin-5/5R $\alpha$   
36  
37  
38 58 (anti-IL5/5R $\alpha$ ) treatment (mepolizumab, reslizumab, benralizumab), anti-interleukin-4R $\alpha$   
39  
40 59 (anti-IL4R $\alpha$ ) treatment (dupilumab), and anti-thymic stromal lymphopoietin (anti-TSLP) treatment  
41  
42  
43 60 (tezepelumab). In previous studies, biologics have been shown to be beneficial for severe asthma,  
44  
45  
46 61 which can reduce the frequency of acute exacerbations and hospitalization, improve lung function  
47  
48 62 and quality of life, and decrease the use of systemic corticosteroids.<sup>[7][8][9]</sup>  
49  
50  
51 63 Recently, there are many systematic reviews and meta-analyses (SRs/MAs) have shown the efficacy  
52  
53 64 of biologics for severe asthma. Nevertheless, it was also mentioned in the SRs/MAs that the  
54  
55  
56 65 reliability of the results may be affected by the heterogeneity among studies and other risks of bias.  
57  
58  
59 66 Methodological quality, reporting quality and evidence quality of these SRs/MAs are still unclear.  
60

The umbrella review can evaluate the overall quality of relevant SRs/MAs in detail, providing high-quality evidence for clinical practice. However, no umbrella reviews or overviews on this topic have been found. Therefore, it is necessary to conduct an umbrella review to evaluate and summarize the published SRs/MAs.

In this umbrella review, the reporting quality, methodological quality and evidence quality of relevant SRs/MAs will be evaluated through applying Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) statement, A Measurement Tool to Assess Reviews (AMSTAR) 2, and Grading of Recommendation Assessment, Development and Evaluation (GRADE) system, respectively. Meanwhile, we will reassess the efficacy of biologics for patients with severe asthma. Ultimately, this study is expected to provide evidence-based medical evidence for the application of biologics for severe asthma.

## 2 METHODS AND ANALYSIS

### 2.1 Design and registration

This protocol is registered in PROSPERO (Registration number: CRD42024607393). The date of first version is October 29, 2024. It will be reported according to Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) statement.<sup>[10]</sup> The detailed PRISMA-P checklist can be found in **Supplementary file 1**. This study is commenced on November 15, 2024 and will complete before May 31, 2025.

### 2.2 Inclusion criteria

#### 2.2.1 Types of participants

This umbrella review will consider SRs/MAs that focus on participants over 12 years old with severe asthma. The criteria for severe asthma will refer to the 2024 Global Initiative for Asthma (GINA).<sup>[6]</sup>



EMBASE, Cochrane Library, Web of Science, and Scopus databases will be searched for literature. We will also review the conference proceedings. The searched period will run from the date of establishment of databases until November 15, 2024. The search terms are showed as follows: “Mepolizumab”, “Reslizumab”, “Benralizumab”, “Omalizumab”, “Dupilumab”, “Tezepelumab”, “Asthma”, “systematic review”, and “meta-analysis”. The search strategy in PubMed database are listed in **Table 1**. The full search strategy are provided in **Supplementary file 2**.

Table 1 Search strategy in PubMed

No	Search terms
#1	((((((((Mepolizumab[MeSH Terms]) OR (Mepolizumab[Title/Abstract]) OR (SB-240563[Title/Abstract])) OR (SB240563[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR (Cinqair[Title/Abstract])) OR (SCH-55700[Title/Abstract])) OR (SCH 55700[Title/Abstract])) OR (SCH55700[Title/Abstract])) OR (DCP-835[Title/Abstract])) OR (DCP 835[Title/Abstract])) OR (DCP835[Title/Abstract])) OR (CEP-38072[Title/Abstract])) OR (CEP38072[Title/Abstract])) OR (((Benralizumab[MeSH Terms]) OR (Benralizumab[Title/Abstract]) OR (MEDI-563[Title/Abstract])) OR (MEDI 563[Title/Abstract])) OR (Fasenra[Title/Abstract])) OR (BIW-8405[Title/Abstract])) OR ((Omalizumab[MeSH Terms]) OR (Xolair[Title/Abstract])) OR (((Dupilumab[MeSH Terms]) OR (Dupilumab[Title/Abstract]) OR (SAR231893[Title/Abstract])) OR (SAR-231893[Title/Abstract])) OR (REGN668[Title/Abstract])) OR (REGN-668[Title/Abstract])) OR (Dupixent[Title/Abstract])) OR (((Tezepelumab[MeSH Terms]) OR (Tezepelumab[Title/Abstract]) OR (MEDI-9929[Title/Abstract])) OR (MEDI9929[Title/Abstract])) OR (MEDI-19929[Title/Abstract])) OR (AMG-157[Title/Abstract])) OR (tezspire[Title/Abstract])) OR (tezepelumab-ekko[Title/Abstract]))



1		
2		
3		
4	#2	(((Asthma[MeSH Terms]) OR (Asthmas[Title/Abstract])) OR (Asthma, Bronchial[Title/Abstract])) OR (Bronchial
5		
6		Asthma[Title/Abstract]))
7		
8		
9	#3	((((((((Meta-Analysis as Topic[MeSH Terms]) OR (Meta Analysis[Publication Type])) OR (meta
10		
11		analysis[Title/Abstract])) OR (meta analyses[Title/Abstract])) OR (meta-analysis[Title/Abstract])) OR
12		
13		(meta-analyses[Title/Abstract])) OR (data pooling[Title/Abstract])) OR (data poolings[Title/Abstract])) OR
14		
15		(clinical trial overview[Title/Abstract])) OR (clinical trial overviews[Title/Abstract])) OR (systematic
16		
17		review[Title/Abstract])) OR (systematic reviews[Title/Abstract]))
18		
19		
20		
21		
22	#4	#1 AND #2 AND #3
23		

25 118 **2.5 Study selection**

26  
27 119 After duplicate removal, two reviewers (QX and YH) will individually examine the titles and  
28  
29  
30 120 abstracts of eligible articles that meet the inclusion and exclusion criteria, and exclude irrelevant  
31  
32  
33 121 studies. EndNote 20 software will be applied to generate citations and remove duplicate articles.<sup>[11]</sup>  
34  
35 122 Then, two authors (QX and YH) will independently review the full texts of remaining articles and  
36  
37  
38 123 determine the final studies included in umbrella review. All disagreements will be resolved by the  
39  
40  
41 124 third independent author (MW). The process of selecting studies is illustrated in **Figure 1**.

42  
43 125 **2.6 Data extraction**

44  
45  
46 126 Data extraction will be conducted by two researchers (BX and YH). We will extract information  
47  
48 127 from eligible SRs/MAs.  
49  
50  
51 128 The extracted information of SRs/MAs include name of first author, year of publication, title of  
52  
53  
54 129 SRs/MAs, country, database searched, number of clinical studies, sample size per group, duration of  
55  
56 130 disease, average age per group, gender ratio per group, type and dose of biologics, treatment  
57  
58  
59 131 duration, type of comparisons, efficacy and safety outcomes, type of effect sizes, effect sizes for  
60

efficacy and safety outcomes, heterogeneity, and publication bias. Any discrepancies will be resolved by discussion.

## 2.7 Quality assessment

### 2.7.1 Reporting quality assessment

The reporting quality of the included SRs/MAs will be evaluated through PRISMA statement.<sup>[12]</sup> It consists of 27 items and is scored as follows. A complete report is worth 1 point, a partial report is worth 0.5 points, and an incomplete report is worth 0 points. The total score of PRISMA statement is 27 points. In the final evaluation, a score of  $\leq 15$  indicates that the report have relatively serious information defects, a score of 15.5 ~ 21 indicates that the report have some defects, and a score of 21.5 ~ 27 indicates that the report is relatively complete.

### 2.7.2 Methodological quality assessment

In this umbrella review, we will assess the methodological quality of included SRs/MAs using the AMSTAR 2 tool.<sup>[13]</sup> It includes 16 items, with 7 key items. The AMSTAR 2's development team recommended focusing on the methodological conditions of key items and giving an overall evaluation. Each item has the following options: yes, partial yes, no. Methodological quality of each SRs/MAs will be categorized as high, moderate, low and critically low.

### 2.7.3 Quality of evidence assessment

In terms of quality of evidence, we will apply the GRADE system to assess in detail.<sup>[14][15]</sup> It will be classified into four grades: high, moderate, low, and critically low. The upgrading factors of the quality of evidence include large effect size, residual confounding, and dose-response relationship, while the degrading factors include limitations of the study, inconsistency, indirectness, publication bias, and imprecision.

1  
2  
3  
4 154 **2.8 Statistical analysis**  
5  
6  
7 155 All analyses will be conducted through “meta” package in R 4.3.3 software. Outcomes will be  
8  
9 156 expressed as mean difference (MD) and risk ratio (RR) with corresponding 95% confidence intervals  
10  
11  
12 157 (CIs). Firstly, we will assess the heterogeneity of included studies by using the Cochrane’s Q test and  
13  
14 158 I<sup>2</sup> statistics.<sup>[16]</sup> P < 0.1 or I<sup>2</sup> > 40% indicates significant heterogeneity, and the random-effects model  
15  
16  
17 159 will be used.<sup>[17]</sup> Or else, we will choose fixed-effects model. Then, we will calculate pooled MDs or  
18  
19  
20 160 RRs with 95%CIs for each outcome of different biologics. The results will be presented clearly by  
21  
22 161 texts, tables and figures. P < 0.05 indicates statistically significant.  
23  
24  
25 162 In addition, subgroup analysis will be conducted to explore the potential source of heterogeneity.  
26  
27  
28 163 The publication bias will be evaluated through the funnel plot and the Egger’s test.  
29

30 164 **3 DISCUSSION**  
31  
32  
33 165 In recent years, many SRs/MAs have emerged. Meanwhile, problems arising from SRs/MAs have  
34  
35 166 also increased. Different study populations and types of studies in included original articles, and  
36  
37  
38 167 varying degrees of methodological defects in SRs/MAs, may lead to misleading clinical decision. As  
39  
40  
41 168 the latest evidence-based medicine analysis method, the umbrella review based on SRs/MAs  
42  
43 169 provides a reliable evidence for clinical practice and makes up the defects of SRs/MAs to some  
44  
45  
46 170 extent.<sup>[18]</sup>

47  
48 171 Asthma is a serious global health problem, and people with severe asthma have more severe  
49  
50  
51 172 symptoms, frequent exacerbations, and medical economy burden.<sup>[19]</sup> In previous SRs/MAs, biologics  
52  
53  
54 173 have good efficacy and safety,<sup>[20][22]</sup> and are considered as the promising treatment for severe  
55  
56 174 asthma. Nevertheless, the overall quality of these SRs/MAs are still unclear, urging us to conduct an  
57  
58  
59 175 umbrella review. The results of this review will further improve the evidence-based medical basis for  
60

the application of biologics for severe asthma and provide a reference for clinical practice.

However, this study has some limitations. Firstly, only articles in English will be included in this study and important studies published in other languages may be omitted. Secondly, some subjective factors may have an effect on the evaluation of literature quality. We will minimize the interference of other factors as much as possible and evaluate the quality of literature according to standards.

## PATIENT AND PUBLIC INVOLVEMENT

Patients and public will not participate in the design and implementation of the study. The research results will be made available to the patient and public.

## ETHICS AND DISSEMINATION

Since this study will use publicly available data, ethics approval is not required. We will disseminate the results of this review through a peer-reviewed journal.

## Author affiliations

<sup>1</sup>National Regional Medical Center of TCM (Pulmonary Disease), the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.

<sup>2</sup>The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, Henan, China.

## Author contributions

QX designed the study, submitted the registration to PROSPERO, and wrote the manuscript. QX and BX completed the search strategy. QX and YH revised the language. MW is responsible for directing the overall study. All authors approved the manuscript.

## Funding

This work was supported by National Key Research and Development Program of China

(2023YFC3502602, 2023YFC3502600), National Natural Science Foundation of China (82474483), Science and Technology Innovation Team of Colleges and Universities of Henan Province (23IRTSTHN027), Special Research Fund of National Traditional Chinese Medicine Clinical Research Base (2022JDZX046), and Project of Science and Technology of Henan Province (232102310472).

**Competing interests**

None declared.

**Patient and public involvement**

Patients and the public will not involve in the design, or implementation, or report, or dissemination plans of this review.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

After completing the study, data are available from corresponding author.

**Supplemental material**

The details of the PRISMA-P checklist and the search strategy can be viewed in Supplemental material.

**REFERENCES**

[1]Porsbjerg C, Melén E, Lehtimäki L, et al. Asthma. *Lancet* 2023;401:858-73. DOI:10.1016/S0140-6736(22)02125-0

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Erasmushogeschool

- [2] Jin G, Liu Y, Wang L, et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. *Nat Immunol* 2024;25:1059-72. DOI:10.1038/s41590-024-01834-9
- [3] Hossny E, Caraballo L, Casale T, et al. Severe asthma and quality of life. *World Allergy Organ J* 2017;10:28. DOI:10.1186/s40413-017-0159-y
- [4] Hekking PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. *J Allergy Clin Immunol* 2015;135:896-902. DOI:10.1016/j.jaci.2014.08.042
- [5] Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. *Can Respir J* 2010;17:74-80. DOI:10.1155/2010/361071
- [6] Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024, Available: <https://ginasthma.org/> [Accessed 22 May 2024].
- [7] Liao J, Tang J, Jiang Y, et al. Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis. *Ther Adv Respir Dis* 2024;18:17534666231221771. DOI:10.1177/17534666231221771
- [8] Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. *J Allergy Clin Immunol* 2017;139:1167-1175.e2. DOI:10.1016/j.jaci.2016.08.008
- [9] Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. *J Asthma* 2017;54:300-7. DOI:10.1080/02770903.2016.1212371
- [10] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.

1  
2  
3  
4 242 DOI:10.1186/2046-4053-4-1  
5  
6  
7 243 [11]Bramer WM. Reference checking for systematic reviews using Endnote. *J Med Libr Assoc*  
8  
9 244 2018;106:542-6. DOI:10.5195/jmla.2018.489  
10  
11  
12 245 [12]Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline  
13  
14 246 for reporting systematic reviews. *BMJ* 2021;372:n71. DOI:10.1136/bmj.n71  
15  
16  
17 247 [13]Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews  
18  
19 248 that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*  
20  
21 249 2017;358:j4008. DOI:10.1136/bmj.j4008  
22  
23  
24 250 [14]Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence  
25  
26 251 profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383-94.  
27  
28 252 DOI:10.1016/j.jclinepi.2010.04.026  
29  
30  
31 253 [15]Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of  
32  
33 254 recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach  
34  
35 255 and grading quality of evidence about interventions. *Allergy* 2009;64:669-77.  
36  
37 256 DOI:10.1111/j.1398-9995.2009.01973.x  
38  
39  
40 257 [16]Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*  
41  
42 258 2003;327:557-60. DOI:10.1136/bmj.327.7414.557  
43  
44  
45 259 [17]Sethi J, Ali MS, Mohananey D, et al. Are Transbronchial Cryobiopsies Ready for Prime Time?:  
46  
47 260 A Systematic Review and Meta-Analysis. *J Bronchology Interv Pulmonol* 2019;26:22-32.  
48  
49 261 DOI:10.1097/LBR.0000000000000519  
50  
51  
52 262 [18]Liu L, Zhang F, Jamali M, et al. The role of vitamin D in diabetic foot ulcer; an umbrella review  
53  
54 263 of meta-analyses. *Front Nutr* 2024;11:1454779. DOI:10.3389/fnut.2024.1454779  
55  
56  
57  
58  
59  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
ErasmusHogeschool

- [19]Le TT, Price DB, Erhard C, et al. Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry. *J Asthma Allergy* 2024;17:1055-69. DOI:10.2147/JAA.S468068
- [20]Tian BP, Zhang GS, Lou J, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. *J Asthma* 2018;55:956-65. DOI:10.1080/02770903.2017.1379534
- [21]Zaazouee MS, Alwarraqi AG, Mohammed YA, et al. Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis. *Front Pharmacol* 2022;13:992731. DOI:10.3389/fphar.2022.992731
- [22]Lin F, Yu B, Deng B, et al. The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2023;102:e34746. DOI:10.1097/MD.00000000000034746

## Figure Legends

Figure 1 Flow chart diagram of study selection.






Figure 1 Flow chart diagram of study selection.

210x297mm (300 x 300 DPI)

## Supplementary file 1

### PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 Checklist: recommended items to address in a systematic review protocol\*

Section and topic	Item No	Checklist item	Page
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	-
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	10
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	-
Support:			
Sources	5a	Indicate sources of financial or other support for the review	10-11
Sponsor	5b	Provide name for the review funder and/or sponsor	10-11
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	10-11
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	2-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	5-6

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned repeats such that it could be repeated	5-6
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently in duplicate), any processes for obtaining and confirming data from investigators	7
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	4-5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	8
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	8-9
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	8-9
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	9
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	-
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	9
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	8

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

**Supplementary file 2.** The details of the search strategy.

Pubmed
<p>((((((((Mepolizumab[MeSH Terms]) OR (SB-240563[Title/Abstract])) OR (SB240563[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR</p> <p>((((((((Reslizumab[MeSH Terms]) OR (Cinqair[Title/Abstract])) OR (SCH-55700[Title/Abstract])) OR (SCH 55700[Title/Abstract])) OR (SCH55700[Title/Abstract])) OR (DCP-835[Title/Abstract])) OR (DCP 835[Title/Abstract])) OR (DCP835[Title/Abstract])) OR (CEP-38072[Title/Abstract])) OR (CEP38072[Title/Abstract])) OR</p> <p>(((Benralizumab[MeSH Terms]) OR (MEDI-563[Title/Abstract])) OR (MEDI 563[Title/Abstract])) OR (Fasenra[Title/Abstract])) OR (BIW-8405[Title/Abstract])) OR</p> <p>((Omalizumab[MeSH Terms]) OR (Xolair[Title/Abstract])) OR</p> <p>((((((Dupilumab[MeSH Terms]) OR (SAR231893[Title/Abstract])) OR (SAR-231893[Title/Abstract])) OR (REGN668[Title/Abstract])) OR (REGN-668[Title/Abstract])) OR (Dupixent[Title/Abstract])) OR</p> <p>((((((Tezepelumab[MeSH Terms]) OR (MEDI-9929[Title/Abstract])) OR (MEDI9929[Title/Abstract])) OR (MEDI-19929[Title/Abstract])) OR (AMG-157[Title/Abstract])) OR (tezspire[Title/Abstract])) OR (tezepelumab-ekko[Title/Abstract])) AND</p> <p>(((Asthma[MeSH Terms]) OR (Asthmas[Title/Abstract])) OR (Asthma, Bronchial[Title/Abstract])) OR (Bronchial Asthma[Title/Abstract])) AND</p> <p>((((((((Meta-Analysis as Topic[MeSH Terms]) OR (Meta Analysis[Publication Type])) OR (meta analysis[Title/Abstract])) OR (meta analyses[Title/Abstract])) OR (meta-analysis[Title/Abstract])) OR (meta-analyses[Title/Abstract])) OR (data pooling[Title/Abstract])) OR (data poolings[Title/Abstract])) OR (clinical trial overview[Title/Abstract])) OR (clinical trial overviews[Title/Abstract])) OR (systematic review[Title/Abstract])) OR (systematic reviews[Title/Abstract]))</p>

Embase
#1 'asthma'/exp
#2 'asthma'
#3 'asthma bronchiale' OR 'asthma pulmonale' OR 'asthma, bronchial' OR 'asthmatic' OR 'asthmatic subject' OR 'bronchial asthma' OR 'bronchus asthma' OR 'chronic asthma' OR 'lung allergy'
#4 #1 OR #2 OR #3
#5 'mepolizumab'/exp
#6 'mepolizumab'
#7 'bat 2606' OR 'bat2606' OR 'bosatria' OR 'nucala' OR 'sb 240563' OR 'sb-240563' OR 'sb240563'
#8 'reslizumab'/exp
#9 'reslizumab'
#10 'cep 38072' OR 'cep38072' OR 'cinquero' OR 'cinqair' OR 'dcp 835' OR 'dcp835' OR 'sch 55700' OR 'sch55700'
#11 'benralizumab'/exp
#12 'benralizumab'
#13 'biw 8405' OR 'biw8405' OR 'fasenra' OR 'khk 4563' OR 'khk4563' OR 'medi 563' OR 'medi563'
#14 'omalizumab'/exp
#15 'omalizumab'
#16 'aomaishu' OR 'cmab 007' OR 'cmab007' OR 'fb 317' OR 'fb317' OR 'gbr 310' OR 'gbr310' OR 'genolair' OR 'gnr 044' OR 'gnr044' OR 'hu 901' OR 'hu901' OR 'monoclonal antibody E 25' OR 'monoclonal antibody E25' OR 'olizumab' OR 'omalizumab alfa' OR 'omalizumab alpha' OR 'omlyclo' OR 'rg 3648' OR 'rg3648' OR

'rhumab 25' OR 'rhumab e25' OR 'sti 004' OR 'sti004' OR 'syn 008' OR 'syn008' OR 'tev 45779' OR 'tev45779' OR 'xolair'	
#17 'dupilumab'/exp	
#18 'dupilumab'	
#19 'bat 2406' OR 'bat2406' OR 'dupixent' OR 'regn 668' OR 'regn668' OR 'sar 231893' OR 'sar231893'	
#20 'tezepelumab'/exp	
#21 'tezepelumab'	
#22 'amg 157' OR 'amg157' OR 'medi 9929' OR 'medi9929' OR 'tezepelumab ekko' OR 'tezepelumab-ekko' OR 'tezspire'	
#23 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22	
#24 #4 AND #23	
<b>Cochrane Library</b>	
#1	MeSH descriptor: [Mepolizumab] explode all trees
#2	MeSH descriptor: [Reslizumab] explode all trees
#3	MeSH descriptor: [Benralizumab] explode all trees
#4	MeSH descriptor: [Omalizumab] explode all trees
#5	Xolair
#6	MeSH descriptor: [Dupilumab] explode all trees
#7	MeSH descriptor: [Tezepelumab] explode all trees
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9	MeSH descriptor: [Asthma] explode all trees

#10	Asthma, Bronchial
#11	Asthmas
#12	Bronchial Asthma
#13	#9 OR #10 OR #11 OR #12
#14	#8 AND #13
<b>Web of Science</b>	
TS = (Mepolizumab OR Reslizumab OR Benralizumab OR Omalizumab OR Dupilumab OR Tezepelumab) AND TS = (Asthma)	
<b>Scopus</b>	
( TITLE-ABS-KEY ( asthma ) ) AND ( ( TITLE-ABS-KEY ( mepolizumab ) OR TITLE-ABS-KEY ( reslizumab ) OR TITLE-ABS-KEY ( benralizumab ) OR TITLE-ABS-KEY ( omalizumab ) OR TITLE-ABS-KEY ( dupilumab ) OR TITLE-ABS-KEY ( tezepelumab ) ) )	

# BMJ Open

## The effectiveness of biologics for patients with severe asthma: study protocol for an umbrella review of systematic reviews and meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-096874.R1
Article Type:	Protocol
Date Submitted by the Author:	09-Mar-2025
Complete List of Authors:	Xiao, Qionghua; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School Xue, Bingyu; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School Huang, Yuanming; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School Wang, Minghang; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease)
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	Asthma < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™  
Manuscripts



1

2

3

4 1     **The effectiveness of biologics for patients with severe asthma: study**

5

6

7 2     **protocol for an umbrella review of systematic reviews and**

8

9 3     **meta-analyses**

10

11

12 4     **Qionghua Xiao<sup>1,2</sup>, Bingyu Xue<sup>1,2</sup>, Yuanming Huang<sup>1,2</sup>, Minghang Wang<sup>1\*</sup>**

13

14 5     <sup>1</sup>National Regional Medical Center of TCM (Pulmonary Disease), the First Affiliated

15

16

17 6     Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.

18

19 7     <sup>2</sup>The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou,

20

21

22 8     Henan, China.

23

24

25 9     **\*Correspondence:**

26

27 10     Minghang Wang

28

29

30 11     E-mail: [wmh107hn@163.com](mailto:wmh107hn@163.com)

31

32

33 12     **Word count:** 2216.

34

35 13     **ABSTRACT**

36

37

38 14     **Introduction:** Many systematic reviews and meta-analyses (SRs/MAs) have evaluated the efficacy

39

40 15     of biologic therapies for severe asthma. However, the overall quality of these SRs/MAs is unclear,

41

42

43 16     which may influence the selection of biologics and lead to misleading clinical decisions. This

44

45

46 17     umbrella review aims to objectively evaluate the overall quality of these SRs/MAs and reassess the

47

48 18     efficacy of biologic therapy for severe asthma. Thus, this study will provide reliable evidence for

49

50

51 19     clinical practice.

52

53 20     **Methods and analysis:** A systematic search will be performed in PubMed, EMBASE, Cochrane

54

55

56 21     Library, Web of Science, Scopus, and conference abstracts up to March 1, 2025. Literature screening

57

58

59 22     and data extraction will be conducted according to predefined inclusion and exclusion criteria. We

60

will evaluate the reporting quality, methodological quality and evidence quality of these SRs/MAs using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) 2, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, respectively. Additionally, the re-meta-analysis of outcomes will be performed using R software (version 4.3.3).

**Ethics and dissemination:** Since this umbrella review will use publicly available data, ethics approval is not required. The results of this study will be disseminated through publication in a peer-reviewed journal.

**PROSPERO registration number:** CRD42024607393.

**Keywords:** biologics, severe asthma, umbrella review, protocol

## Article Summary

### Strengths and limitations of this study

- (1) This study is the first umbrella review of systematic reviews and meta-analyses (SRs/MAs) that evaluate the efficacy of biologic therapy for patients with severe asthma.
- (2) This umbrella review will objectively evaluate the overall quality of eligible SRs/MAs.
- (3) Only articles in English will be included in this study, which may result in the exclusion of potentially relevant studies published in other languages.
- (4) Potential subjective bias may influence the evaluation of literature quality.

## 1 INTRODUCTION

Asthma is a prevalent chronic respiratory disease characterized by airway inflammation and airway hyperresponsiveness. It often presents with recurrent wheezing, shortness of breath, chest tightness, cough, and other symptoms.<sup>[1]</sup> Asthma is a serious global health problem, affecting about 300 million

1  
2  
3  
4 45 people worldwide and causing about 250,000 deaths annually.<sup>[2]</sup> Additionally, and more importantly,  
5  
6 46 patients with severe asthma have more significant symptoms, more frequent exacerbations, and more  
7  
8  
9 47 serious adverse effects of medications, which can interfere with patients' daily life, sleep, and  
10  
11  
12 48 physical activity.<sup>[3]</sup> A Dutch study reported that about 3.7% of people with asthma suffer from severe  
13  
14 49 asthma.<sup>[4]</sup> Furthermore, severe asthma is associated with higher healthcare expenditures. A Canadian  
15  
16  
17 50 study demonstrated that severe asthma accounts for over 60% of total asthma-related costs.<sup>[5]</sup>  
18  
19  
20 51 Severe asthma refers to patients who remain uncontrolled despite adhering to maximal optimized  
21  
22 52 high-dose inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) treatment and  
23  
24  
25 53 management of associated factors, or who worsen when high-dose treatment is decreased.<sup>[6]</sup> For  
26  
27 54 these patients, add-on therapy, mainly emerging biologics, are needed to provide new hope for the  
28  
29  
30 55 treatment of severe asthma. Biologics can modulate the immuno-inflammatory cascade in the  
31  
32  
33 56 pathological course of severe asthma by precisely targeting inflammatory cytokines.<sup>[6]</sup> Biologics for  
34  
35 57 severe asthma mainly include anti-immunoglobulin E (anti-IgE) treatment (e.g., omalizumab),  
36  
37  
38 58 anti-interleukin-5/5R $\alpha$  (anti-IL-5/5R $\alpha$ ) treatment (e.g., mepolizumab, reslizumab, benralizumab),  
39  
40  
41 59 anti-interleukin-4R $\alpha$  (anti-IL-4R $\alpha$ ) treatment (e.g., dupilumab), and anti-thymic stromal  
42  
43 60 lymphopoietin (anti-TSLP) treatment (e.g., tezepelumab). In previous studies, biologics have been  
44  
45  
46 61 shown to be beneficial for severe asthma, which can reduce the frequency of acute exacerbations and  
47  
48  
49 62 hospitalizations, improve lung function and quality of life, and decrease reliance on systemic  
50  
51 63 corticosteroids.<sup>[7][8][9]</sup>  
52  
53 64 Recently, numerous systematic reviews and meta-analyses (SRs/MAs) have demonstrated the  
54  
55  
56 65 efficacy of biologics for severe asthma. However, these SRs/MAs also highlighted potential  
57  
58  
59 66 limitations. The reliability of the results may be affected by the heterogeneity among studies and  
60

other risks of bias. The methodological, reporting, and evidence quality of these SRs/MAs remain unclear. The umbrella review can evaluate the overall quality of relevant SRs/MAs in detail, thereby providing high-quality evidence for clinical practice. To date, no umbrella reviews have been published on this topic, underscoring the need for this study to synthesize existing evidence.

In this umbrella review, the reporting, methodological, and evidence quality of relevant SRs/MAs will be evaluated through using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system, respectively. Additionally, we will re-evaluate the efficacy of biologics for patients with severe asthma. Ultimately, this study aims to provide evidence-based medical analysis and summary for the use of biologics in severe asthma.

## 2 METHODS AND ANALYSIS

### 2.1 Design and registration

This protocol was registered in PROSPERO (Registration number: CRD42024607393). The initial version was registered on October 29, 2024. It will be reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) 2015 statement.<sup>[10]</sup> The detailed PRISMA-P 2015 checklist can be found in **Supplementary File 1**. This study commenced on November 15, 2024, and is expected to be completed by May 31, 2025.

### 2.2 Inclusion criteria

#### 2.2.1 Types of participants

This umbrella review will consider SRs/MAs that focus on participants over 12 years old with severe asthma. The criteria for severe asthma will refer to the 2024 Global Initiative for Asthma (GINA).<sup>[6]</sup>

1  
2  
3  
4 89 2.2.2 Types of interventions  
5  
6  
7 90 All participants with severe asthma received routine therapy with high-dose ICS-LABA  
8  
9 91 combinations. Biologic therapies were administered strictly as add-on treatments to this background  
10  
11  
12 92 regimen. The investigated biologics included anti-IgE treatment (omalizumab), anti-IL-5/5Rα  
13  
14 93 treatment (mepolizumab, reslizumab, benralizumab), anti-IL-4Rα treatment (dupilumab), and  
15  
16  
17 94 anti-TSLP treatment (tezepelumab).<sup>[6]</sup>  
18  
19  
20 95 2.2.3 Types of comparisons  
21  
22 96 The control group will be given routine therapy or corresponding placebos.  
23  
24  
25 97 2.2.4 Types of outcomes  
26  
27 98 The literature is required to report 1 or more of the following outcomes: annualized asthma  
28  
29  
30 99 exacerbation rate (AER), the change from baseline in oral corticosteroids (OCS) dosage, the change  
31  
32  
33 100 from baseline in pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV1), asthma  
34  
35 101 control questionnaire (ACQ), asthma control test (ACT), asthma quality of life questionnaire  
36  
37  
38 102 (AQLQ), number of hospitalizations due to asthma, blood eosinophil count, and fractional exhaled  
39  
40 103 nitric oxide (FeNO) levels.  
41  
42  
43 104 Moreover, we will collect information regarding adverse events and serious adverse events caused  
44  
45  
46 105 by biologic therapy. Thus, we can evaluate the safety of biologics in patients with asthma.  
47  
48 106 2.2.5 Types of studies  
49  
50  
51 107 This study will only include eligible SRs/MAs of randomized controlled trials (RCTs) for analysis.  
52  
53 108 **2.3 Exclusion criteria**  
54  
55  
56 109 Studies meeting any of the following criteria will be excluded: (1) Articles for which the full text is  
57  
58  
59 110 not available, (2) Articles without available data, (3) Duplicate or retracted studies, (4) Articles in a  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

language other than English.

2.4 Search strategy

Two authors (QX and BX) will independently carry out the retrieval of literature. PubMed, EMBASE, Cochrane Library, Web of Science, and Scopus databases will be searched for literature. Conference abstracts from the American Thoracic Society International Conference and the European Respiratory Society International Congress will also be searched. The search period will cover from the inception of each database to March 1, 2025. The search terms used include: “Mepolizumab”, “Reslizumab”, “Benralizumab”, “Omalizumab”, “Dupilumab”, “Tezepelumab”, “Asthma”, “systematic review”, “meta-analysis”, and “indirect treatment comparison”. The search strategy used in PubMed database is listed in Table 1. The full search strategy is provided in Supplementary File 2.

Table 1 Search strategy in PubMed

No	Search terms
#1	((((((((Mepolizumab[MeSH Terms]) OR (Mepolizumab[Title/Abstract]) OR (SB-240563[Title/Abstract])) OR (SB240563[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR (Cinqair[Title/Abstract])) OR (SCH-55700[Title/Abstract])) OR (SCH 55700[Title/Abstract])) OR (SCH55700[Title/Abstract])) OR (DCP-835[Title/Abstract])) OR (DCP 835[Title/Abstract])) OR (DCP835[Title/Abstract])) OR (CEP-38072[Title/Abstract])) OR (CEP38072[Title/Abstract])) OR (((Benralizumab[MeSH Terms]) OR (Benralizumab[Title/Abstract]) OR (MEDI-563[Title/Abstract])) OR (MEDI 563[Title/Abstract])) OR (Fasenra[Title/Abstract])) OR (BIW-8405[Title/Abstract])) OR ((Omalizumab[MeSH Terms]) OR (Xolair[Title/Abstract])) OR (((Dupilumab[MeSH Terms]) OR (Dupilumab[Title/Abstract]) OR

1

2

3

4 (SAR231893[Title/Abstract])) OR (SAR-231893[Title/Abstract])) OR (REGN668[Title/Abstract])) OR

5

6 (REGN-668[Title/Abstract])) OR (Dupixent[Title/Abstract])) OR ((((((Tezepelumab[MeSH Terms]) OR

7

8 (Tezepelumab[Title/Abstract]) OR (MEDI-9929[Title/Abstract])) OR (MEDI9929[Title/Abstract])) OR

9

10 (MEDI-19929[Title/Abstract])) OR (AMG-157[Title/Abstract])) OR (tezspire[Title/Abstract])) OR

11

12 (tezpelumab-ekko[Title/Abstract]))

13

14

15

16

17 #2 (((Asthma[MeSH Terms]) OR (Asthmas[Title/Abstract])) OR (Asthma, Bronchial[Title/Abstract])) OR (Bronchial

18

19 Asthma[Title/Abstract]))

20

21

22 #3 (((((((((((Meta-Analysis as Topic[MeSH Terms]) OR (Meta Analysis[Publication Type])) OR (meta

23

24 analysis[Title/Abstract])) OR (meta analyses[Title/Abstract])) OR (meta-analysis[Title/Abstract])) OR

25

26 (meta-analyses[Title/Abstract])) OR (data pooling[Title/Abstract])) OR (data poolings[Title/Abstract])) OR

27

28 (clinical trial overview[Title/Abstract])) OR (clinical trial overviews[Title/Abstract])) OR (systematic

29

30 review[Title/Abstract])) OR (systematic reviews[Title/Abstract])) OR (indirect treatment comparison

31

32 [Title/Abstract]))

33

34

35

36

37

38 #4 #1 AND #2 AND #3

39

40 123 **2.5 Study selection**

41

42

43 124 After removal of duplicate studies, two reviewers (QX and YH) will individually examine the titles

44

45

46 125 and abstracts of eligible articles that meet the inclusion and exclusion criteria, and exclude irrelevant

47

48 126 studies. EndNote 20 software will be used to generate citations and remove duplicate articles.<sup>[11]</sup>

49

50

51 127 Then, two authors (QX and YH) will independently review the full texts of remaining articles and

52

53 128 determine the final studies to be included in umbrella review. All disagreements will be resolved by

54

55

56 129 the third independent author (MW). The process of selecting studies is illustrated in **Figure 1**.

57

58

59 130 To prevent the double-counting of data, we will implement a systematic approach to manage

60



overlapping primary studies across included SRs/MAs. Initially, we will create a comprehensive inventory of all primary studies and identify any overlaps. Then, we will exclude duplicate data to ensure that data from each primary study are included only once. Additionally, if multiple SRs/MAs include the same primary studies, the datasets may be merged. In the final umbrella review, we will report the methods used to handle overlapping primary studies.

## 2.6 Data extraction

Data extraction will be conducted by two researchers (BX and YH). We will extract information from eligible SRs/MAs. The extracted information of SRs/MAs includes name of first author, year of publication, title of SRs/MAs, country, database searched, number of clinical studies, sample size per group, disease duration, average age per group, gender ratio per group, type and dose of biologics, treatment duration, type of comparisons, blood eosinophil count, FeNO, IgE, sIgE levels, efficacy and safety outcomes, type of effect sizes, effect sizes for efficacy and safety outcomes, heterogeneity, and publication bias. Any discrepancies will be resolved by discussion.

To enhance the depth and robustness of our analysis, firstly, we will extract GRADE ratings (e.g., high, moderate, low, very low) for critical outcomes from SRs/MAs. Furthermore, we will also collect information on the methodological quality of these SRs/MAs using tools like AMSTAR 2, including the name and version of the assessment tool used, its core evaluation criteria or domains, assigned scores, and any conclusions drawn regarding the certainty of the evidence.

## 2.7 Quality assessment

All quality assessments will be conducted by two independent reviewers (QX and YH). Discrepancies will be resolved by consulting a third reviewer (MW). Before the quality assessment process, all reviewers will participate in a training session focused on the use of these quality



1  
2  
3  
4 153 assessment tools to enhance inter-rater agreement and minimize bias.  
5  
6  
7 154 2.7.1 Reporting quality assessment  
8  
9 155 The reporting quality of the included SRs/MAs will be evaluated using the PRISMA 2020  
10  
11  
12 156 statement.<sup>[12]</sup> It consists of 27 items and is scored as follows. A complete report is worth 1 point, a  
13  
14 157 partial report is worth 0.5 points, and an incomplete report is worth 0 points. If all required content is  
15  
16  
17 158 reported, the item will be classified as "complete report", if  $\geq 50\%$  of the reported content is reported  
18  
19  
20 159 with some key information missing, it will be classified as "partial report", if  $< 50\%$  of the reported  
21  
22 160 content is reported or critical elements are missing, it will be classified as "incomplete report". The  
23  
24  
25 161 total score of PRISMA statement is 27 points. In the final evaluation, a score of  $\leq 15$  indicates that  
26  
27 162 the report has relatively serious information defects, a score of 15.5-21 indicates that the report has  
28  
29  
30 163 some defects, and a score of 21.5-27 indicates that the report is relatively complete.<sup>[13]</sup>  
31  
32  
33 164 2.7.2 Risk of bias (Methodological quality) assessment  
34  
35 165 In this umbrella review, we will assess the methodological quality of included SRs/MAs using the  
36  
37  
38 166 AMSTAR 2 tool.<sup>[14]</sup> It includes 16 items, with 7 key items. The AMSTAR 2's development team  
39  
40 167 recommended focusing on the methodological conditions of key items and determining the overall  
41  
42  
43 168 quality. Each item has the following options: yes, partial yes, no. Methodological quality of each  
44  
45  
46 169 SR/MA will be categorized as high, moderate, low and critically low.  
47  
48 170 Furthermore, we will assess the risk of bias of primary studies through seven aspects: random  
49  
50  
51 171 sequence generation (selection bias), allocation concealment (selection bias), blinding of participants  
52  
53  
54 172 and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete  
55  
56 173 outcome data (attrition bias), selective reporting (reporting bias) and other bias.<sup>[15]</sup> In our final  
57  
58  
59 174 review, we will report these assessments, discussing their potential impact on the overall  
60

conclusions.

### 2.7.3 Quality of evidence assessment

In terms of quality of evidence, we will apply the GRADE system to assess.<sup>[16][17]</sup> It will be classified into four grades: high, moderate, low, and very low. The upgrading factors for evidence quality include large effect size, residual confounding, dose-response relationship, and adequate sample size, while the degrading factors include limitations of the study, inconsistency, indirectness, publication bias, and imprecision.

## 2.8 Management of duplicate reports

To address duplicate publications systematically, we will implement manual verification to identify potential duplicates based on overlapping titles, author affiliations, trial registration numbers, and data characteristics. Confirmed duplicates will be resolved by prioritizing the most recent publication to capture methodological updates. If publications are within 6 months of each other, the study with the larger sample size and more comprehensive data will be selected. All decisions will be reviewed independently by two researchers, with discrepancies resolved through consensus. The entire process will be thoroughly documented to ensure reproducibility.

## 2.9 Statistical analysis

All analyses will be conducted through “meta” package in R 4.3.3 software. Outcomes will be expressed as mean difference (MD) and risk ratio (RR) with corresponding 95% confidence intervals (CIs). Firstly, we will assess the heterogeneity of included studies by using the Cochran’s Q test and  $I^2$  statistics.<sup>[18]</sup>  $P < 0.1$  or  $I^2 > 40\%$  indicates significant heterogeneity, and the random-effects model will be used.<sup>[19]</sup> Or else, we will choose the fixed-effects model. Then, we will calculate pooled MDs or RRs with 95% CIs for each outcome of different biologics. The results will be presented in text,

1  
2  
3  
4 197 tables, and figures.  $P < 0.05$  indicates statistical significance.  
5  
6  
7 198 In addition, subgroup analysis will be conducted to explore the potential sources of heterogeneity.  
8  
9 199 The subgroups will include population characteristics (age, baseline disease severity, and blood  
10  
11  
12 200 eosinophil count) and intervention variables (types of biologics, dosage, and treatment duration). The  
13  
14  
15 201 publication bias will be evaluated through the funnel plot and the Egger's test, which will only be  
16  
17 202 performed when the number of studies exceeds 10 to ensure sufficient statistical power.  
18

19  
20 203 **3 DISCUSSION**

21  
22 204 In recent years, many SRs/MAs have been published. However, concerns have been raised as the  
23  
24  
25 205 generalizability and validity of such analyses. Different study populations and types of original  
26  
27  
28 206 studies, combined with varying degrees of methodological flaws in SRs/MAs, may lead to  
29  
30 207 misleading clinical decisions. Employing the latest evidence-based medicine analysis, the umbrella  
31  
32  
33 208 review based on SRs/MAs provides more robust and reliable evidence for clinical practice and  
34  
35 209 partially compensates for the limitations of individual SRs/MAs. [20]  
36

37  
38 210 Asthma is a serious global health problem, and people with severe asthma have more severe  
39  
40  
41 211 symptoms, frequent exacerbations, and significant medical economic burden.[21] In previous  
42  
43 212 SRs/MAs, biologics have demonstrated promising efficacy and safety,[22][23][24] and are considered a  
44  
45  
46 213 promising treatment for severe asthma. Nevertheless, the overall quality of these SRs/MAs is still  
47  
48 214 unclear, promoting the need for an umbrella review. The findings of this review will further  
49  
50  
51 215 strengthen the evidence-based medical basis for the application of biologics in severe asthma and  
52  
53 216 provide guidance for clinical practice.  
54

55  
56 217 Sample size is a critical factor influencing the reliability of SRs/MAs. Adequate sample size  
57  
58  
59 218 enhances the precision of effect estimates and reduces the risk of bias, both of which are essential for  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

high-quality evidence. Therefore, incorporating sample size as an additional factor in the GRADE system can provide a more comprehensive evaluation of the evidence quality. In this study, we will pay special attention to the sample size of included SRs/MAs to ensure the robustness of our findings.

However, this study has some limitations. Firstly, only articles in English will be included in this study, and important studies published in other languages may be excluded. As most databases and literature resources are in English, language restrictions ensure data accuracy and consistency, which facilitates precise data extraction and analysis. Secondly, some subjective factors may affect the evaluation of literature quality.

## PATIENT AND PUBLIC INVOLVEMENT

Patients and public will not participate in the design and implementation of the study. The research results will be made available to the patient and public.

## ETHICS AND DISSEMINATION

Since this study will use publicly available data, ethics approval is not required. We will disseminate the results of this review through a peer-reviewed journal.

## Author affiliations

<sup>1</sup>National Regional Medical Center of TCM (Pulmonary Disease), the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.

<sup>2</sup>The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, Henan, China.

## Author contributions

QX designed the study, submitted the registration to PROSPERO, and wrote the manuscript. QX and

1  
2  
3  
4 241 BX completed the search strategy. QX and YH revised the language. MW is responsible for directing  
5  
6  
7 242 the overall study. All authors approved the manuscript.  
8

9 243 **Funding**

10  
11  
12 244 This work was supported by National Key Research and Development Program of China  
13  
14 245 (2023YFC3502602, 2023YFC3502600), National Natural Science Foundation of China  
15  
16  
17 246 (82474483), Science and Technology Innovation Team of Colleges and Universities of  
18  
19  
20 247 Henan Province (23IRTSTHN027), Special Research Fund of National Traditional Chinese  
21  
22 248 Medicine Clinical Research Base (2022JDZX046), and Project of Science and Technology of  
23  
24  
25 249 Henan Province (232102310472).  
26

27 250 **Competing interests**

28  
29  
30 251 None declared.  
31

32 252 **Patient and public involvement**

33  
34  
35 253 Patients and the public will not involve in the design, or implementation, or report, or dissemination  
36  
37  
38 254 plans of this review.  
39

40 255 **Patient consent for publication**

41  
42  
43 256 Not applicable.  
44

45 257 **Provenance and peer review**

46  
47  
48 258 Not commissioned; externally peer reviewed.  
49

50 259 **Data availability statement**

51  
52  
53 260 After completing the study, data are available from corresponding author.  
54  
55

56 261 **Supplemental material**

57  
58  
59 262 The details of the PRISMA-P 2015 checklist and the search strategy can be viewed in Supplemental  
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

material.

## REFERENCES

- [1] Porsbjerg C, Melén E, Lehtimäki L, et al. Asthma. *Lancet* 2023;401:858-73. DOI:10.1016/S0140-6736(22)02125-0
- [2] Jin G, Liu Y, Wang L, et al. A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice. *Nat Immunol* 2024;25:1059-72. DOI:10.1038/s41590-024-01834-9
- [3] Hossny E, Caraballo L, Casale T, et al. Severe asthma and quality of life. *World Allergy Organ J* 2017;10:28. DOI:10.1186/s40413-017-0159-y
- [4] Hekking PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. *J Allergy Clin Immunol* 2015;135:896-902. DOI:10.1016/j.jaci.2014.08.042
- [5] Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British Columbia. *Can Respir J* 2010;17:74-80. DOI:10.1155/2010/361071
- [6] Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024, Available: <https://ginasthma.org/> [Accessed 22 May 2024].
- [7] Liao J, Tang J, Jiang Y, et al. Effects of omalizumab on lung function in patients with moderate-to-severe allergic asthma: a systematic review and meta-analysis. *Ther Adv Respir Dis* 2024;18:17534666231221771. DOI:10.1177/17534666231221771
- [8] Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. *J Allergy Clin Immunol* 2017;139:1167-75.e2. DOI:10.1016/j.jaci.2016.08.008
- [9] Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the

1  
2  
3  
4 285 treatment of severe asthma: a systematic review and indirect treatment comparison. *J Med Econ*  
5  
6 286 2022;25:679-90. DOI:10.1080/13696998.2022.2074195  
7  
8  
9 287 [10]Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and  
10  
11 meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1.  
12 288  
13  
14 289 DOI:10.1186/2046-4053-4-1  
15  
16  
17 290 [11]Bramer WM. Reference checking for systematic reviews using Endnote. *J Med Libr Assoc*  
18  
19 291 2018;106:542-6. DOI:10.5195/jmla.2018.489  
20  
21  
22 292 [12]Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline  
23  
24 for reporting systematic reviews. *BMJ* 2021;372:n71. DOI:10.1136/bmj.n71  
25 293  
26  
27 294 [13]Lu X, Yang Z, Liu F, et al. Effectiveness of non-pharmacological treatments for postpartum  
28  
29 depression: an umbrella review protocol. *BMJ Open* 2023;13:e066395.  
30 295  
31  
32 296 DOI:10.1136/bmjopen-2022-066395  
33  
34  
35 297 [14]Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews  
36  
37 that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*  
38 298  
39 2017;358:j4008. DOI:10.1136/bmj.j4008  
40 299  
41  
42 [15]Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing  
43 300  
44 risk of bias in randomised trials. *BMJ* 2011;343:d5928. DOI:10.1136/bmj.d5928  
45 301  
46  
47 [16]Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence  
48 302  
49 profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383-94.  
50 303  
51  
52 DOI:10.1016/j.jclinepi.2010.04.026  
53 304  
54  
55 [17]Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of  
56 305  
57 recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach  
58 306  
59  
60



- and grading quality of evidence about interventions. *Allergy* 2009;64:669-77.  
DOI:10.1111/j.1398-9995.2009.01973.x
- [18] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60. DOI:10.1136/bmj.327.7414.557
- [19] Sethi J, Ali MS, Mohananey D, et al. Are Transbronchial Cryobiopsies Ready for Prime Time?: A Systematic Review and Meta-Analysis. *J Bronchology Interv Pulmonol* 2019;26:22-32. DOI:10.1097/LBR.0000000000000519
- [20] Liu L, Zhang F, Jamali M, et al. The role of vitamin D in diabetic foot ulcer; an umbrella review of meta-analyses. *Front Nutr* 2024;11:1454779. DOI:10.3389/fnut.2024.1454779
- [21] Le TT, Price DB, Erhard C, et al. Disease Burden and Access to Biologic Therapy in Patients with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry. *J Asthma Allergy* 2024;17:1055-69. DOI:10.2147/JAA.S468068
- [22] Tian BP, Zhang GS, Lou J, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. *J Asthma* 2018;55:956-65. DOI:10.1080/02770903.2017.1379534
- [23] Zaazouee MS, Alwarraqi AG, Mohammed YA, et al. Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis. *Front Pharmacol* 2022;13:992731. DOI:10.3389/fphar.2022.992731
- [24] Lin F, Yu B, Deng B, et al. The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2023;102:e34746. DOI:10.1097/MD.00000000000034746

## Figure Legends



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1 Flow chart diagram of study selection.

For peer review only

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool




Figure 1 Flow chart diagram of study selection.

210x297mm (300 x 300 DPI)

Supplementary file 1  
PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 Checklist: recommended items to address in a systematic review protocol\*

Section and topic	Item No	Checklist item	Page
ADMINISTRATIVE INFORMATION			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	-
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	12-13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	-
Support:			
Sources	5a	Indicate sources of financial or other support for the review	13
Sponsor	5b	Provide name for the review funder and/or sponsor	13
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	13
INTRODUCTION			
Rationale	6	Describe the rationale for the review in the context of what is already known	2-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
METHODS			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned repeats such that it could be repeated	6
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications	4-5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	9
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	10
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ )	10
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	-
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	11
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	10

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

Supplementary file 2. The details of the search strategy.

Pubmed
<p>((((((((((Mepolizumab[MeSH Terms]) OR (SB-240563[Title/Abstract])) OR (SB240563[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR</p> <p>((((((((((Reslizumab[MeSH Terms]) OR (Cinqair[Title/Abstract])) OR (SCH-55700[Title/Abstract])) OR (SCH 55700[Title/Abstract])) OR (SCH55700[Title/Abstract])) OR (DCP-835[Title/Abstract])) OR (DCP 835[Title/Abstract])) OR (DCP835[Title/Abstract])) OR (CEP-38072[Title/Abstract])) OR (CEP38072[Title/Abstract])))) OR</p> <p>(((((Benralizumab[MeSH Terms]) OR (MEDI-563[Title/Abstract])) OR (MEDI 563[Title/Abstract])) OR (Fasenra[Title/Abstract])) OR (BIW-8405[Title/Abstract])) OR</p> <p>((Omalizumab[MeSH Terms]) OR (Xolair[Title/Abstract])) OR</p> <p>(((((Dupilumab[MeSH Terms]) OR (SAR231893[Title/Abstract])) OR (SAR-231893[Title/Abstract])) OR (REGN668[Title/Abstract])) OR (REGN-668[Title/Abstract])) OR (Dupixent[Title/Abstract])) OR</p> <p>((((((Tezepelumab[MeSH Terms]) OR (MEDI-9929[Title/Abstract])) OR (MEDI9929[Title/Abstract])) OR (MEDI-19929[Title/Abstract])) OR (AMG-157[Title/Abstract])) OR (tezspire[Title/Abstract])) OR (tezepelumab-ekko[Title/Abstract])) AND</p> <p>((((Asthma[MeSH Terms]) OR (Asthmas[Title/Abstract])) OR (Asthma, Bronchial[Title/Abstract])) OR (Bronchial Asthma[Title/Abstract])) AND</p> <p>((((((((((((((Meta-Analysis as Topic[MeSH Terms]) OR (Meta Analysis[Publication Type])) OR (meta analysis[Title/Abstract])) OR (meta analyses[Title/Abstract])) OR (meta-analysis[Title/Abstract])) OR (meta-analyses[Title/Abstract])) OR (data pooling[Title/Abstract])) OR (data poolings[Title/Abstract])) OR (clinical trial overview[Title/Abstract])) OR (clinical trial overviews[Title/Abstract])) OR</p>

## Supplementary Material

<p>(systematic review[Title/Abstract])) OR (systematic reviews[Title/Abstract])) OR (indirect treatment comparison [Title/Abstract]))</p>
<p><b>Embase</b></p>
<p>#1 'asthma'/exp</p> <p>#2 'asthma'</p> <p>#3 'asthma bronchiale' OR 'asthma pulmonale' OR 'asthma, bronchial' OR 'asthmatic' OR 'asthmatic subject' OR 'bronchial asthma' OR 'bronchus asthma' OR 'chronic asthma' OR 'lung allergy'</p> <p>#4 #1 OR #2 OR #3</p> <p>#5 'mepolizumab'/exp</p> <p>#6 'mepolizumab'</p> <p>#7 'bat 2606' OR 'bat2606' OR 'bosatria' OR 'nucala' OR 'sb 240563' OR 'sb-240563' OR 'sb240563'</p> <p>#8 'reslizumab'/exp</p> <p>#9 'reslizumab'</p> <p>#10 'cep 38072' OR 'cep38072' OR 'cinquaero' OR 'cinqair' OR 'dcp 835' OR 'dcp835' OR 'sch 55700' OR 'sch55700'</p> <p>#11 'benralizumab'/exp</p> <p>#12 'benralizumab'</p> <p>#13 'biw 8405' OR 'biw8405' OR 'fasenra' OR 'khk 4563' OR 'khk4563' OR 'medi 563' OR 'medi563'</p> <p>#14 'omalizumab'/exp</p> <p>#15 'omalizumab'</p>

#16 'aomaishu' OR 'cmab 007' OR 'cmab007' OR 'fb 317' OR 'fb317' OR 'gbr 310' OR 'gbr310' OR 'genolair' OR 'gnr 044' OR 'gnr044' OR 'hu 901' OR 'hu901' OR 'monoclonal antibody E 25' OR 'monoclonal antibody E25' OR 'olizumab' OR 'omalizumab alfa' OR 'omalizumab alpha' OR 'omlyclo' OR 'rg 3648' OR 'rg3648' OR 'rhumab 25' OR 'rhumab e25' OR 'sti 004' OR 'sti004' OR 'syn 008' OR 'syn008' OR 'tev 45779' OR 'tev45779' OR 'xolair'	
#17 'dupilumab'/exp	
#18 'dupilumab'	
#19 'bat 2406' OR 'bat2406' OR 'dupixent' OR 'regn 668' OR 'regn668' OR 'sar 231893' OR 'sar231893'	
#20 'tezepelumab'/exp	
#21 'tezepelumab'	
#22 'amg 157' OR 'amg157' OR 'medi 9929' OR 'medi9929' OR 'tezepelumab ekko' OR 'tezepelumab-ekko' OR 'tezspire'	
#23 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22	
#24 #4 AND #23	
<b>Cochrane Library</b>	
#1	MeSH descriptor: [Mepolizumab] explode all trees
#2	MeSH descriptor: [Reslizumab] explode all trees
#3	MeSH descriptor: [Benralizumab] explode all trees
#4	MeSH descriptor: [Omalizumab] explode all trees
#5	Xolair
#6	MeSH descriptor: [Dupilumab] explode all trees

## Supplementary Material

#7	MeSH descriptor: [Tezepelumab] explode all trees
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9	MeSH descriptor: [Asthma] explode all trees
#10	Asthma, Bronchial
#11	Asthmas
#12	Bronchial Asthma
#13	#9 OR #10 OR #11 OR #12
#14	#8 AND #13
<b>Web of Science</b>	
TS = (Mepolizumab OR Reslizumab OR Benralizumab OR Omalizumab OR Dupilumab OR Tezepelumab) AND TS = (Asthma)	
<b>Scopus</b>	
( TITLE-ABS-KEY ( asthma ) ) AND ( ( TITLE-ABS-KEY ( mepolizumab ) OR TITLE-ABS-KEY ( reslizumab ) OR TITLE-ABS-KEY ( benralizumab ) OR TITLE-ABS-KEY ( omalizumab ) OR TITLE-ABS-KEY ( dupilumab ) OR TITLE-ABS-KEY ( tezepelumab ) ) )	



# BMJ Open

## The effectiveness of biologics for patients with severe asthma: study protocol for an umbrella review of systematic reviews and meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2024-096874.R2
Article Type:	Protocol
Date Submitted by the Author:	24-Mar-2025
Complete List of Authors:	Xiao, Qionghua; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School Xue, Bingyu; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School Huang, Yuanming; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease); Henan University of Chinese Medicine, The First Clinical Medical School Wang, Minghang; The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, National Regional Medical Center of TCM (Pulmonary Disease)
<b>Primary Subject Heading</b>:	Respiratory medicine
Secondary Subject Heading:	Respiratory medicine
Keywords:	Asthma < THORACIC MEDICINE, Protocols & guidelines < HEALTH SERVICES ADMINISTRATION & MANAGEMENT, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™  
Manuscripts

1

2

3

41The effectiveness of biologics for patients with severe asthma: study

5

62protocol for an umbrella review of systematic reviews and

7

8

93meta-analyses

10

11

124Qionghua Xiao<sup>1,2</sup>, Bingyu Xue<sup>1,2</sup>, Yuanming Huang<sup>1,2</sup>, Minghang Wang<sup>1\*</sup>

13

145<sup>1</sup>National Regional Medical Center of TCM (Pulmonary Disease), the First Affiliated

15

166Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, China.

17

18

197<sup>2</sup>The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou,

20

218Henan, China.

22

23

249\*Correspondence:

25

26

2710Minghang Wang

28

29

3011E-mail: [wmh107hn@163.com](mailto:wmh107hn@163.com)

31

32

3312Word count: 2510.

34

3513ABSTRACT

36

37

3814Introduction: Many systematic reviews and meta-analyses (SRs/MAs) have evaluated the efficacy

39

4015of biologic therapies for severe asthma. However, the overall quality of these SRs/MAs is unclear,

41

4216which may influence the selection of biologics and lead to misleading clinical decisions. This

43

4417umbrella review aims to objectively evaluate the overall quality of these SRs/MAs and reassess the

45

4618efficacy of biologic therapies for severe asthma. Thus, this study will provide reliable evidence for

47

4819clinical practice.

49

50

5120Methods and analysis: A systematic search will be performed in PubMed, Embase, Cochrane

52

5321Library, Web of Science, Scopus, and conference abstracts up to March 1, 2025. Literature screening

54

5522and data extraction will be conducted according to predefined inclusion and exclusion criteria. We

56

57

58

59

60

will evaluate the reporting quality, methodological quality, and evidence quality of these SRs/MAs using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, PRISMA for Network Meta-Analysis (PRISMA-NMA) 2015 checklist, A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, Cochrane Risk of Bias 1.0 (RoB 1.0), and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Additionally, the re-analysis of outcomes will be performed using R software (version 4.3.3).

**Ethics and dissemination:** Since this umbrella review will use publicly available data, ethics approval is not required. The results of this study will be disseminated through publication in a peer-reviewed journal.

**PROSPERO registration number:** CRD42024607393.

**Keywords:** biologics, severe asthma, umbrella review, protocol

## Article Summary

### Strengths and limitations of this study

(1) This study is the first umbrella review that evaluates the efficacy of biologic therapies for patients with severe asthma.

(2) This umbrella review will objectively evaluate the overall quality of eligible SRs/MAs.

(3) Only articles in English will be included in this study, which may result in the exclusion of potentially relevant studies published in other languages.

(4) Potential subjective bias may influence the evaluation of literature quality.

## 1 INTRODUCTION

Asthma is a prevalent chronic respiratory disease characterized by airway inflammation and airway hyperresponsiveness. It often presents with recurrent wheezing, shortness of breath, chest tightness,

1  
2  
3  
4 45 cough, and other symptoms.<sup>[1]</sup> Asthma is a serious global health problem, affecting about 300 million  
5  
6 46 people worldwide and causing about 250,000 deaths annually.<sup>[2]</sup> Additionally, and more importantly,  
7  
8  
9 47 patients with severe asthma have more significant symptoms, more frequent exacerbations, and more  
10  
11  
12 48 serious adverse effects of medications, which can interfere with patients' daily lives, sleep, and  
13  
14 49 physical activity.<sup>[3]</sup> A Dutch study reported that about 3.7% of people with asthma suffer from severe  
15  
16  
17 50 asthma.<sup>[4]</sup> Furthermore, severe asthma is associated with higher healthcare expenditures. A Canadian  
18  
19  
20 51 study demonstrated that severe asthma accounts for over 60% of total asthma-related costs.<sup>[5]</sup>  
21  
22 52 Severe asthma refers to patients who remain uncontrolled despite adhering to maximal optimized  
23  
24  
25 53 high-dose inhaled corticosteroids (ICS)/long-acting beta-agonists (LABA) treatment and  
26  
27 54 management of associated factors, or who worsen when high-dose treatment is decreased.<sup>[6]</sup> For  
28  
29  
30 55 these patients, add-on therapies, mainly emerging biologics, are needed to provide new hope for the  
31  
32  
33 56 treatment of severe asthma. Biologics can modulate the immuno-inflammatory cascade in the  
34  
35 57 pathological course of severe asthma by precisely targeting inflammatory cytokines.<sup>[6]</sup> Biologics for  
36  
37  
38 58 severe asthma mainly include anti-immunoglobulin E (anti-IgE) treatment (e.g., omalizumab),  
39  
40 59 anti-interleukin-5/5R $\alpha$  (anti-IL-5/5R $\alpha$ ) treatment (e.g., mepolizumab, reslizumab, benralizumab),  
41  
42  
43 60 anti-interleukin-4R $\alpha$  (anti-IL-4R $\alpha$ ) treatment (e.g., dupilumab), and anti-thymic stromal  
44  
45 61 lymphopoietin (anti-TSLP) treatment (e.g., tezepelumab). In previous studies, biologics have been  
46  
47  
48 62 shown to be beneficial for severe asthma, as they can reduce the frequency of acute exacerbations  
49  
50  
51 63 and hospitalizations, improve lung function and quality of life, and decrease reliance on systemic  
52  
53 64 corticosteroids.<sup>[7][8][9]</sup>  
54  
55  
56 65 Recently, numerous systematic reviews and meta-analyses (SRs/MAs) have demonstrated the  
57  
58  
59 66 efficacy of biologics for severe asthma. However, these SRs/MAs also highlighted potential  
60

limitations. The reliability of the results may be affected by the heterogeneity among studies and other risks of bias. The methodological, reporting, and evidence quality of these SRs/MAs remain unclear. The umbrella review can evaluate the overall quality of relevant SRs/MAs in detail, thereby providing high-quality evidence for clinical practice. To date, no umbrella reviews have been published on this topic, underscoring the need for this study to synthesize existing evidence.

In this umbrella review, the reporting, methodological, and evidence quality of relevant SRs/MAs will be evaluated using Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 statement, PRISMA for Network Meta-Analysis (PRISMA-NMA) 2015 checklist, A MeaSurement Tool to Assess Systematic Reviews (AMSTAR) 2, Cochrane Risk of Bias 1.0 (RoB 1.0), and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system. Additionally, we will re-evaluate the efficacy of biologics for patients with severe asthma. Ultimately, this study aims to provide evidence-based medical analysis for the use of biologics in severe asthma.

## 2 METHODS AND ANALYSIS

### 2.1 Design and registration

This protocol was registered in PROSPERO (Registration number: CRD42024607393). The initial version was registered on October 29, 2024. It will be reported according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocol (PRISMA-P) 2015 statement.<sup>[10]</sup> The detailed PRISMA-P 2015 checklist can be found in **Supplementary file 1**. This study commenced on November 15, 2024, and is expected to be completed by May 31, 2025.

### 2.2 Inclusion criteria

#### 2.2.1 Types of participants

1  
2  
3  
4 89 This umbrella review will consider SRs/MAs that focus on participants aged  $\geq 12$  years with severe  
5  
6 90 asthma. While the PROSPERO registration included participants aged  $\geq 6$  years, the final analysis  
7  
8  
9 91 will be restricted to  $\geq 12$  years due to insufficient high-quality evidence in younger populations. This  
10  
11  
12 92 adjustment ensures consistency with clinical practice and avoids bias from limited data. The criteria  
13  
14 93 for severe asthma will refer to the 2024 Global Initiative for Asthma (GINA).<sup>[6]</sup>

17 94 2.2.2 Types of interventions

19 95 All participants with severe asthma received routine therapy with high-dose ICS-LABA  
20  
21  
22 96 combinations. Biologic therapies were administered strictly as add-on treatments to this background  
23  
24  
25 97 regimen. The investigated biologics included anti-IgE treatment (omalizumab), anti-IL-5/5R $\alpha$   
26  
27 98 treatment (mepolizumab, reslizumab, benralizumab), anti-IL-4R $\alpha$  treatment (dupilumab), and  
28  
29  
30 99 anti-TSLP treatment (tezepelumab).<sup>[6]</sup>

32 100 2.2.3 Types of comparisons

35 101 The control group will be given routine therapy or corresponding placebos.

38 102 2.2.4 Types of outcomes

40 103 The literature is required to report 1 or more of the following outcomes: annualized asthma  
41  
42  
43 104 exacerbation rate (AER), the change from baseline in oral corticosteroids (OCS) dosage, the change  
44  
45  
46 105 from baseline in pre-bronchodilator forced expiratory volume in 1 second (pre-BD FEV1), asthma  
47  
48 106 control questionnaire (ACQ), asthma control test (ACT), asthma quality of life questionnaire  
49  
50  
51 107 (AQLQ), number of hospitalizations due to asthma, blood eosinophil count, and fractional exhaled  
52  
53 108 nitric oxide (FeNO) levels.

56 109 Moreover, we will collect information regarding adverse events and serious adverse events caused  
57  
58  
59 110 by biologic therapy. Thus, we can evaluate the safety of biologics in patients with asthma.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

111 2.2.5 Types of studies

112 This study will include eligible SRs/MAs of randomized controlled trials (RCTs) for analysis.  
113 Notably, we will also include articles on indirect treatment comparisons (ITCs) in our umbrella  
114 review, such as network meta-analyses (NMAs).

115 2.3 Exclusion criteria

116 Studies meeting any of the following criteria will be excluded: (1) Articles for which the full text is  
117 not available, (2) Articles without available data, (3) Duplicate or retracted studies, (4) Articles in a  
118 language other than English.

119 2.4 Search strategy

120 Two authors (QX and BX) will independently carry out the retrieval of literature. PubMed, Embase,  
121 Cochrane Library, Web of Science, and Scopus databases will be searched for literature. Conference  
122 abstracts from the American Thoracic Society International Conference, the European Respiratory  
123 Society International Congress, the CHEST Annual Meeting (American College of Chest  
124 Physicians), and the Asia Pacific Society of Respiriology Congress will also be searched. The search  
125 will cover the period from the inception of each database to March 1, 2025. The search terms used  
126 include: “Mepolizumab”, “Reslizumab”, “Benralizumab”, “Omalizumab”, “Dupilumab”,  
127 “Tezepelumab”, “Asthma”, “systematic review”, “meta-analysis”, and “indirect treatment  
128 comparison”. The search strategy used in the PubMed database is listed in **Table 1**. The full search  
129 strategy is provided in **Supplementary file 2**.

130 Table 1 Search strategy in PubMed

No	Search terms
#1	((((((((((Mepolizumab[MeSH Terms]) OR (Mepolizumab[Title/Abstract]) OR (SB-240563[Title/Abstract])) OR

1		
2		
3		
4		(SB240563[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR
5		
6		(((((Reslizumab[MeSH Terms]) OR (Reslizumab[Title/Abstract]) OR (Cinqair[Title/Abstract])) OR
7		
8		
9		(SCH-55700[Title/Abstract])) OR (SCH 55700[Title/Abstract])) OR (SCH55700[Title/Abstract])) OR
10		
11		
12		(DCP-835[Title/Abstract])) OR (DCP 835[Title/Abstract])) OR (DCP835[Title/Abstract])) OR
13		
14		(CEP-38072[Title/Abstract])) OR (CEP38072[Title/Abstract])) OR (((Benralizumab[MeSH Terms]) OR
15		
16		(Benralizumab[Title/Abstract]) OR (MEDI-563[Title/Abstract])) OR (MEDI 563[Title/Abstract])) OR
17		
18		
19		(Fasenra[Title/Abstract])) OR (BIW-8405[Title/Abstract])) OR ((Omalizumab[MeSH Terms]) OR
20		
21		
22		(Xolair[Title/Abstract])) OR (((Dupilumab[MeSH Terms]) OR (Dupilumab[Title/Abstract]) OR
23		
24		
25		(SAR231893[Title/Abstract])) OR (SAR-231893[Title/Abstract])) OR (REGN668[Title/Abstract])) OR
26		
27		
28		(REGN-668[Title/Abstract])) OR (Dupixent[Title/Abstract])) OR (((Tezepelumab[MeSH Terms]) OR
29		
30		(Tezepelumab[Title/Abstract]) OR (MEDI-9929[Title/Abstract])) OR (MEDI9929[Title/Abstract])) OR
31		
32		
33		(MEDI-19929[Title/Abstract])) OR (AMG-157[Title/Abstract])) OR (tezspire[Title/Abstract])) OR
34		
35		(tezepelumab-ekko[Title/Abstract]))
36		
37		
38	#2	(((((Asthma[MeSH Terms]) OR (Asthmas[Title/Abstract])) OR (Asthma, Bronchial[Title/Abstract])) OR (Bronchial
39		
40		Asthma[Title/Abstract]))
41		
42		
43	#3	(((((Meta-Analysis as Topic[MeSH Terms]) OR (Meta Analysis[Publication Type])) OR (meta
44		
45		analysis[Title/Abstract])) OR (meta analyses[Title/Abstract])) OR (meta-analysis[Title/Abstract])) OR
46		
47		
48		(meta-analyses[Title/Abstract])) OR (data pooling[Title/Abstract])) OR (data poolings[Title/Abstract])) OR
49		
50		
51		(clinical trial overview[Title/Abstract])) OR (clinical trial overviews[Title/Abstract])) OR (systematic
52		
53		review[Title/Abstract])) OR (systematic reviews[Title/Abstract])) OR (indirect treatment comparison
54		
55		
56		[Title/Abstract]))
57		
58	#4	#1 AND #2 AND #3
59		
60		



## 2.5 Study selection

After removal of duplicate studies, two reviewers (QX and YH) will individually examine the titles and abstracts of eligible articles that meet the inclusion and exclusion criteria, and exclude irrelevant studies. EndNote (version 20) software will be used to generate citations and remove duplicate articles.<sup>[11]</sup> Then, two authors (QX and YH) will independently review the full texts of remaining articles and determine the final studies to be included in the umbrella review. All disagreements will be resolved by the third independent author (MW). The process of selecting studies is illustrated in

### Figure 1.

To prevent the double counting of data, we will implement a systematic approach to manage overlapping primary studies across included SRs/MAs. Initially, we will create a comprehensive inventory of all primary studies and identify any overlaps. Then, we will exclude duplicate data to ensure that data from each primary study are included only once. Additionally, if multiple SRs/MAs include the same primary studies, the datasets may be merged. In the final umbrella review, we will report the methods used to handle overlapping primary studies.

## 2.6 Data extraction

Data extraction will be conducted by two researchers (BX and YH). We will extract information from eligible SRs/MAs. Extracted information from each SR/MA includes name of first author, year of publication, title of SR/MA, country, databases searched, number of clinical studies, sample sizes per group, disease duration, average age per group, gender ratio per group, type and dose of biologics, treatment duration, type of comparisons, blood eosinophil count, FeNO, IgE, sIgE levels, efficacy and safety outcomes, type of effect sizes, effect sizes for efficacy and safety outcomes, heterogeneity, and publication bias. Any discrepancies will be resolved by discussion.

1  
2  
3  
4 153 To enhance the depth and robustness of our analysis, firstly, we will extract GRADE ratings (e.g.,  
5  
6 154 high, moderate, low, or very low) for critical outcomes from SRs/MAs. Furthermore, we will also  
7  
8  
9 155 collect information on the methodological quality of these SRs/MAs using tools like AMSTAR 2,  
10  
11  
12 156 including the name and version of the assessment tool used, its core evaluation criteria or domains,  
13  
14 157 assigned scores, and any conclusions drawn regarding the certainty of the evidence.  
15  
16

17 158 **2.7 Quality assessment**

18  
19  
20 159 All quality assessments will be conducted by two independent reviewers (QX and YH).  
21  
22 160 Discrepancies will be resolved by consulting a third reviewer (MW). Before the quality assessment  
23  
24  
25 161 process, all reviewers will participate in a training session focused on the use of these quality  
26  
27 162 assessment tools to enhance inter-rater agreement and minimize bias.  
28  
29

30 163 **2.7.1 Reporting quality assessment**

31  
32  
33 164 The reporting quality of the included SRs/MAs will be evaluated using the PRISMA 2020  
34  
35 165 statement.<sup>[12]</sup> It consists of 27 items and is scored as follows: a complete report is worth 1 point, a  
36  
37  
38 166 partial report is worth 0.5 points, and an incomplete report is worth 0 points. If all required content is  
39  
40 167 reported, the item will be classified as “complete report”; if  $\geq 50\%$  of the reported content is reported  
41  
42  
43 168 with some key information missing, it will be classified as “partial report”; if  $< 50\%$  of the reported  
44  
45 169 content is reported or critical elements are missing, it will be classified as “incomplete report”. The  
46  
47  
48 170 total score of PRISMA statement is 27 points. In the final evaluation, a score of  $\leq 15$  indicates that  
49  
50  
51 171 the report has relatively serious information defects, a score of 15.5-21 indicates that the report has  
52  
53 172 some defects, and a score of 21.5-27 indicates that the report is relatively complete.<sup>[13]</sup>  
54  
55

56 173 Additionally, the PRISMA-NMA 2015 checklist will be used to assess the reporting quality of the  
57  
58 174 included ITCs.<sup>[14]</sup> It includes 32 items, and the total score is 32 points. Scoring follows the same  
59  
60

criteria as the PRISMA 2020 statement. In the final evaluation, a score of  $\leq 18$  indicates that the report has relatively serious information defects, a score of 18.5-25 indicates that the report has some defects, and a score of 25.5-32 indicates that the report is relatively complete.

## 2.7.2 Risk of bias (Methodological quality) assessment

In this umbrella review, we will assess the methodological quality of included SRs/MAs using the AMSTAR 2 tool.<sup>[15]</sup> It includes 16 items, with 7 key items. The AMSTAR 2 development team recommended focusing on the methodological conditions of key items and determining the overall quality. Each item has the following options: yes, partial yes, or no. The methodological quality of each SR/MA will be categorized as high, moderate, low, or critically low.

The methodological quality of ITCs will be assessed using the AMSTAR 2 tool, augmented with NMA-specific criteria from the International Society for Pharmacoeconomics and Outcomes Research, Academy of Managed Care Pharmacy, National Pharmaceutical Council (ISPOR-AMCP-NPC) checklist.<sup>[16]</sup> The four criteria include transitivity assessment, direct and indirect evidence consistency, model selection justification, and cautious interpretation of rankings. Each item is rated yes, partial yes, or no, with overall quality categorized as high, moderate, low, or critically low.

Furthermore, we will assess the risk of bias of primary studies through seven aspects: random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), selective reporting (reporting bias) and other bias.<sup>[17]</sup> In our final review, we will report these assessments, discussing their potential impact on the overall conclusions.

1  
2  
3  
4 197 2.7.3 Quality of evidence assessment  
5  
6  
7 198 In terms of quality of evidence, we will apply the GRADE system to assess it.<sup>[18][19]</sup> It will be  
8  
9 199 classified into four grades: high, moderate, low, and very low. The upgrading factors for evidence  
10  
11 200 quality include large effect size, residual confounding, dose-response relationship, and adequate  
12  
13  
14 201 sample size, while the degrading factors include study limitations, inconsistency, indirectness,  
15  
16  
17 202 publication bias, and imprecision.  
18

19  
20 203 **2.8 Management of duplicate reports**  
21

22 204 To systematically address duplicate publications, we will implement manual verification to identify  
23  
24 205 potential duplicates based on overlapping titles, author affiliations, trial registration numbers, and  
25  
26  
27 206 data characteristics. Confirmed duplicates will be resolved by prioritizing the most recent publication  
28  
29  
30 207 to capture methodological updates. If publications are within 6 months of each other, the study with  
31  
32  
33 208 the larger sample size and more comprehensive data will be selected. All decisions will be reviewed  
34  
35 209 independently by two researchers, and discrepancies will be resolved through consensus. The entire  
36  
37  
38 210 process will be thoroughly documented to ensure reproducibility.  
39

40 211 **2.9 Statistical analysis**  
41

42  
43 212 All analyses will be conducted through “meta” package in R 4.3.3 software. Outcomes will be  
44  
45 213 expressed as mean difference (MD) and risk ratio (RR) with corresponding 95% confidence intervals  
46  
47  
48 214 (CIs). Firstly, we will assess the heterogeneity of included studies by using the Cochran’s Q test and  
49  
50  
51 215 I<sup>2</sup> statistics.<sup>[20]</sup> P<0.1 or I<sup>2</sup>>40% indicates significant heterogeneity, and the random-effects model  
52  
53 216 will be used.<sup>[21]</sup> Otherwise, we will choose the fixed-effects model. Then, we will calculate pooled  
54  
55  
56 217 MDs or RRs with 95% CIs for each outcome of different biologics. The results will be presented in  
57  
58  
59 218 the text, tables, and figures. P<0.05 indicates statistical significance.  
60

Data from ITC and direct comparison articles will be analyzed together. Sensitivity analysis will also be conducted to evaluate the impact of each study on overall results. When interpreting the results, evidence from both ITC and direct comparison articles will be considered to provide a more comprehensive efficacy assessment. Due to the uncertainty of ITC results, we will interpret the findings cautiously.

In addition, subgroup analysis will be conducted to explore the potential sources of heterogeneity. The subgroups will include population characteristics (age, baseline disease severity, and blood eosinophil count) and intervention variables (types of biologics, dosage, and treatment duration). The publication bias will be evaluated through funnel plots and Egger's test, which will only be performed when the number of studies exceeds 10 to ensure sufficient statistical power.

### 3 DISCUSSION

In recent years, many SRs/MAs have been published. However, concerns have been raised about the generalizability and validity of such analyses. Different study populations and types of original studies, combined with varying degrees of methodological flaws in SRs/MAs, may lead to misleading clinical decisions. Employing the latest evidence-based medicine analysis, the umbrella review based on SRs/MAs provides more robust and reliable evidence for clinical practice and compensates for the limitations of individual SRs/MAs.<sup>[22]</sup>

Asthma is a serious global health problem, and people with severe asthma have more severe symptoms, frequent exacerbations, and significant medical economic burden.<sup>[23]</sup> In previous SRs/MAs, biologics have demonstrated promising efficacy and safety, and are considered a promising treatment for severe asthma.<sup>[24][26]</sup> Nevertheless, the overall quality of these SRs/MAs is still unclear, prompting the need for an umbrella review. The findings of this review will further

1  
2  
3  
4 241 strengthen the evidence-based medical basis for the application of biologics in severe asthma and  
5  
6  
7 242 provide guidance for clinical practice.  
8

9 243 Sample size is a critical factor influencing the reliability of SRs/MAs. Adequate sample size  
10  
11  
12 244 enhances the precision of effect estimates and reduces the risk of bias, both of which are essential for  
13  
14 245 high-quality evidence. Therefore, incorporating sample size as an additional factor in the GRADE  
15  
16  
17 246 system can provide a more comprehensive evaluation of the quality of evidence. In this study, we  
18  
19  
20 247 will pay special attention to the sample size of included SRs/MAs to ensure the robustness of our  
21  
22 248 findings.  
23

24  
25 249 However, this study has some limitations. Firstly, we will include only articles in English and  
26  
27 250 exclude studies published in other languages. As most databases and literature resources are in  
28  
29  
30 251 English, language restrictions help ensure data accuracy and consistency, thereby facilitating precise  
31  
32  
33 252 data extraction and analysis. Secondly, some subjective factors may affect the evaluation of literature  
34  
35 253 quality.  
36

37  
38 254 **PATIENT AND PUBLIC INVOLVEMENT**  
39

40 255 Patients and public will not participate in the design and implementation of the study. The research  
41  
42  
43 256 results will be made available to the patient and public.  
44

45  
46 257 **ETHICS AND DISSEMINATION**  
47

48 258 Since this study will use publicly available data, ethics approval is not required. We will disseminate  
49  
50  
51 259 the results of this review through a peer-reviewed journal.  
52

53 260 **Author affiliations**  
54

55  
56 261 <sup>1</sup>National Regional Medical Center of TCM (Pulmonary Disease), the First Affiliated Hospital of  
57  
58  
59 262 Henan University of Chinese Medicine, Zhengzhou, Henan, China.  
60

<sup>2</sup>The First Clinical Medical School, Henan University of Chinese Medicine, Zhengzhou, Henan, China.

### **Author contributions**

Qionghua Xiao designed the study, submitted the registration to PROSPERO, and wrote the manuscript. Qionghua Xiao and Bingyu Xue completed the search strategy. Qionghua Xiao and Yuanming Huang revised the language. Minghang Wang is responsible for directing the overall study. Minghang Wang is the guarantor.

### **Funding**

This work was supported by National Key Research and Development Program of China (2023YFC3502602), National Natural Science Foundation of China (82474483), Science and Technology Innovation Team of Colleges and Universities of Henan Province (23IRTSTHN027), Special Research Fund of National Traditional Chinese Medicine Clinical Research Base (2022JDZX046), and Project of Science and Technology of Henan Province (232102310472).

### **Competing interests**

None declared.

### **Patient and public involvement**

Patients and the public will not involve in the design, or implementation, or report, or dissemination plans of this review.

### **Patient consent for publication**

Not applicable.

### **Provenance and peer review**



1  
2  
3  
4 285 Not commissioned; externally peer reviewed.  
5  
6  
7 286 **Data availability statement**  
8  
9 287 After completing the study, data are available from corresponding author.  
10  
11  
12 288 **Supplemental material**  
13  
14 289 The details of the PRISMA-P 2015 checklist and the search strategy can be viewed in Supplemental  
15  
16  
17 290 material.  
18  
19  
20 291 **REFERENCES**  
21  
22 292 [1]Porsbjerg C, Melén E, Lehtimäki L, et al. Asthma. *Lancet* 2023;401:858-73.  
23  
24  
25 293 DOI:10.1016/S0140-6736(22)02125-0  
26  
27 294 [2]Jin G, Liu Y, Wang L, et al. A single infusion of engineered long-lived and multifunctional T  
28  
29  
30 295 cells confers durable remission of asthma in mice. *Nat Immunol* 2024;25:1059-72.  
31  
32  
33 296 DOI:10.1038/s41590-024-01834-9  
34  
35 297 [3]Hossny E, Caraballo L, Casale T, et al. Severe asthma and quality of life. *World Allergy Organ J*  
36  
37  
38 298 2017;10:28. DOI:10.1186/s40413-017-0159-y  
39  
40 299 [4]Hekking PW, Wener RR, Amelink M, et al. The prevalence of severe refractory asthma. *J Allergy*  
41  
42  
43 300 *Clin Immunol* 2015;135:896-902. DOI:10.1016/j.jaci.2014.08.042  
44  
45  
46 301 [5]Sadatsafavi M, Lynd L, Marra C, et al. Direct health care costs associated with asthma in British  
47  
48 302 Columbia. *Can Respir J* 2010;17:74-80. DOI:10.1155/2010/361071  
49  
50  
51 303 [6]Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention.  
52  
53 304 2024, Available: <https://ginasthma.org/> [Accessed 22 May 2024].  
54  
55  
56 305 [7]Liao J, Tang J, Jiang Y, et al. Effects of omalizumab on lung function in patients with  
57  
58  
59 306 moderate-to-severe allergic asthma: a systematic review and meta-analysis. *Ther Adv Respir Dis*  
60



2024;18:17534666231221771. DOI:10.1177/17534666231221771

[8] Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. *J Allergy Clin Immunol* 2017;139:1167-75.e2. DOI:10.1016/j.jaci.2016.08.008

[9] Menzies-Gow A, Steenkamp J, Singh S, et al. Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. *J Med Econ* 2022;25:679-90. DOI:10.1080/13696998.2022.2074195

[10] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1. DOI:10.1186/2046-4053-4-1

[11] Bramer WM. Reference checking for systematic reviews using Endnote. *J Med Libr Assoc* 2018;106:542-6. DOI:10.5195/jmla.2018.489

[12] Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021;372:n71. DOI:10.1136/bmj.n71

[13] Lu X, Yang Z, Liu F, et al. Effectiveness of non-pharmacological treatments for postpartum depression: an umbrella review protocol. *BMJ Open* 2023;13:e066395. DOI:10.1136/bmjopen-2022-066395

[14] Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. *Ann Intern Med* 2015;162:777-84. DOI:10.7326/M14-2385

[15] Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*

2017;358:j4008. DOI:10.1136/bmj.j4008

[16]Jansen JP, Trikalinos T, Cappelleri JC, et al. Indirect treatment comparison/network meta-analysis study questionnaire to assess relevance and credibility to inform health care decision making: an ISPOR-AMCP-NPC Good Practice Task Force report. *Value Health* 2014;17:157-73. DOI:10.1016/j.jval.2014.01.004

[17]Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928. DOI:10.1136/bmj.d5928

[18]Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;64:383-94. DOI:10.1016/j.jclinepi.2010.04.026

[19]Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines. Part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. *Allergy* 2009;64:669-77. DOI:10.1111/j.1398-9995.2009.01973.x

[20]Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ* 2003;327:557-60. DOI:10.1136/bmj.327.7414.557

[21]Sethi J, Ali MS, Mohananey D, et al. Are Transbronchial Cryobiopsies Ready for Prime Time?: A Systematic Review and Meta-Analysis. *J Bronchology Interv Pulmonol* 2019;26:22-32. DOI:10.1097/LBR.0000000000000519

[22]Liu L, Zhang F, Jamali M, et al. The role of vitamin D in diabetic foot ulcer; an umbrella review of meta-analyses. *Front Nutr* 2024;11:1454779. DOI:10.3389/fnut.2024.1454779

[23]Le TT, Price DB, Erhard C, et al. Disease Burden and Access to Biologic Therapy in Patients

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.  
Erasmus Hogeschool

- with Severe Asthma, 2017-2022: An Analysis of the International Severe Asthma Registry. *J Asthma Allergy* 2024;17:1055-69. DOI:10.2147/JAA.S468068
- [24] Tian BP, Zhang GS, Lou J, et al. Efficacy and safety of benralizumab for eosinophilic asthma: A systematic review and meta-analysis of randomized controlled trials. *J Asthma* 2018;55:956-65. DOI:10.1080/02770903.2017.1379534
- [25] Zaazouee MS, Alwarraqi AG, Mohammed YA, et al. Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis. *Front Pharmacol* 2022;13:992731. DOI:10.3389/fphar.2022.992731
- [26] Lin F, Yu B, Deng B, et al. The efficacy and safety of tezepelumab in the treatment of uncontrolled asthma: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore)* 2023;102:e34746. DOI:10.1097/MD.00000000000034746

## Figure Legends

Figure 1 Flow chart diagram of study selection.




Figure 1 Flow chart diagram of study selection.

210x297mm (300 x 300 DPI)

## Supplementary file 1

### PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 Checklist: recommended items to address in a systematic review protocol\*

Section and topic	Item No	Checklist item	Page
<b>ADMINISTRATIVE INFORMATION</b>			
Title:			
Identification	1a	Identify the report as a protocol of a systematic review	1
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	-
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number	2
Authors:			
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author	1
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	12-13
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	-
Support:			
Sources	5a	Indicate sources of financial or other support for the review	13
Sponsor	5b	Provide name for the review funder and/or sponsor	13
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	13
<b>INTRODUCTION</b>			
Rationale	6	Describe the rationale for the review in the context of what is already known	2-4
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	4
<b>METHODS</b>			
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review	4-5
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage	6

Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned repeats such that it could be repeated	6
Study records:			
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	7-8
Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis)	7-8
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms, done independently in duplicate), any processes for obtaining and confirming data from investigators	8
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), pre-planned data assumptions and simplifications	4-5
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	5
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	9
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised	10
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as I <sup>2</sup> , Kendall's $\tau$ )	10
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression)	11
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	-
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies)	11
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE)	10

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015 Jan 2;349(jan02 1):g7647.*

**Supplementary file 2.** The details of the search strategy.

Pubmed
<p>((((((((Mepolizumab[MeSH Terms]) OR (SB-240563[Title/Abstract])) OR (SB240563[Title/Abstract])) OR (Nucala[Title/Abstract])) OR (Bosatria[Title/Abstract])) OR</p> <p>((((((((Reslizumab[MeSH Terms]) OR (Cinqair[Title/Abstract])) OR (SCH-55700[Title/Abstract])) OR (SCH 55700[Title/Abstract])) OR (SCH55700[Title/Abstract])) OR (DCP-835[Title/Abstract])) OR (DCP 835[Title/Abstract])) OR (DCP835[Title/Abstract])) OR (CEP-38072[Title/Abstract])) OR (CEP38072[Title/Abstract])) OR</p> <p>((((Benralizumab[MeSH Terms]) OR (MEDI-563[Title/Abstract])) OR (MEDI 563[Title/Abstract])) OR (Fasenra[Title/Abstract])) OR (BIW-8405[Title/Abstract])) OR</p> <p>((Omalizumab[MeSH Terms]) OR (Xolair[Title/Abstract])) OR</p> <p>((((Dupilumab[MeSH Terms]) OR (SAR231893[Title/Abstract])) OR (SAR-231893[Title/Abstract])) OR (REGN668[Title/Abstract])) OR (REGN-668[Title/Abstract])) OR (Dupixent[Title/Abstract])) OR</p> <p>((((Tezepelumab[MeSH Terms]) OR (MEDI-9929[Title/Abstract])) OR (MEDI9929[Title/Abstract])) OR (MEDI-19929[Title/Abstract])) OR (AMG-157[Title/Abstract])) OR (tezspire[Title/Abstract])) OR (tezepelumab-ekko[Title/Abstract])) AND</p> <p>(((Asthma[MeSH Terms]) OR (Asthmas[Title/Abstract])) OR (Asthma, Bronchial[Title/Abstract])) OR (Bronchial Asthma[Title/Abstract])) AND</p> <p>((((((((((((Meta-Analysis as Topic[MeSH Terms]) OR (Meta Analysis[Publication Type])) OR (meta analysis[Title/Abstract])) OR (meta analyses[Title/Abstract])) OR (meta-analysis[Title/Abstract])) OR (meta-analyses[Title/Abstract])) OR (data pooling[Title/Abstract])) OR (data poolings[Title/Abstract])) OR (clinical trial overview[Title/Abstract])) OR (clinical trial overviews[Title/Abstract])) OR</p>

(systematic review[Title/Abstract])) OR (systematic reviews[Title/Abstract])) OR (indirect treatment comparison [Title/Abstract]))
<b>Embase</b>
#1 'asthma'/exp
#2 'asthma'
#3 'asthma bronchiale' OR 'asthma pulmonale' OR 'asthma, bronchial' OR 'asthmatic' OR 'asthmatic subject' OR 'bronchial asthma' OR 'bronchus asthma' OR 'chronic asthma' OR 'lung allergy'
#4 #1 OR #2 OR #3
#5 'mepolizumab'/exp
#6 'mepolizumab'
#7 'bat 2606' OR 'bat2606' OR 'bosatria' OR 'nucala' OR 'sb 240563' OR 'sb- 240563' OR 'sb240563'
#8 'reslizumab'/exp
#9 'reslizumab'
#10 'cep 38072' OR 'cep38072' OR 'cinquaero' OR 'cinqair' OR 'dcp 835' OR 'dcp835' OR 'sch 55700' OR 'sch55700'
#11 'benralizumab'/exp
#12 'benralizumab'
#13 'biw 8405' OR 'biw8405' OR 'fasenra' OR 'khk 4563' OR 'khk4563' OR 'medi 563' OR 'medi563'
#14 'omalizumab'/exp
#15 'omalizumab'



<p>#16 'aomaishu' OR 'cmab 007' OR 'cmab007' OR 'fb 317' OR 'fb317' OR 'gbr 310' OR 'gbr310' OR 'genolair' OR 'gnr 044' OR 'gnr044' OR 'hu 901' OR 'hu901' OR 'monoclonal antibody E 25' OR 'monoclonal antibody E25' OR 'olizumab' OR 'omalizumab alfa' OR 'omalizumab alpha' OR 'omlyclo' OR 'rg 3648' OR 'rg3648' OR 'rhumab 25' OR 'rhumab e25' OR 'sti 004' OR 'sti004' OR 'syn 008' OR 'syn008' OR 'tev 45779' OR 'tev45779' OR 'xolair'</p> <p>#17 'dupilumab'/exp</p> <p>#18 'dupilumab'</p> <p>#19 'bat 2406' OR 'bat2406' OR 'dupixent' OR 'regn 668' OR 'regn668' OR 'sar 231893' OR 'sar231893'</p> <p>#20 'tezepelumab'/exp</p> <p>#21 'tezepelumab'</p> <p>#22 'amg 157' OR 'amg157' OR 'medi 9929' OR 'medi9929' OR 'tezepelumab ekko' OR 'tezepelumab-ekko' OR 'tezspire'</p> <p>#23 #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22</p> <p>#24 #4 AND #23</p>	
<b>Cochrane Library</b>	
#1	MeSH descriptor: [Mepolizumab] explode all trees
#2	MeSH descriptor: [Reslizumab] explode all trees
#3	MeSH descriptor: [Benralizumab] explode all trees
#4	MeSH descriptor: [Omalizumab] explode all trees
#5	Xolair
#6	MeSH descriptor: [Dupilumab] explode all trees

#7	MeSH descriptor: [Tezepelumab] explode all trees
#8	#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7
#9	MeSH descriptor: [Asthma] explode all trees
#10	Asthma, Bronchial
#11	Asthmas
#12	Bronchial Asthma
#13	#9 OR #10 OR #11 OR #12
#14	#8 AND #13
<b>Web of Science</b>	
TS = (Mepolizumab OR Reslizumab OR Benralizumab OR Omalizumab OR Dupilumab OR Tezepelumab) AND TS = (Asthma)	
<b>Scopus</b>	
( TITLE-ABS-KEY ( asthma ) ) AND ( ( TITLE-ABS-KEY ( mepolizumab ) OR TITLE-ABS-KEY ( reslizumab ) OR TITLE-ABS-KEY ( benralizumab ) OR TITLE-ABS-KEY ( omalizumab ) OR TITLE-ABS-KEY ( dupilumab ) OR TITLE-ABS-KEY ( tezepelumab ) ) )	